Latest Reports

US Government Drug Reimbursement (PH204)

In the United States, attaining formulary position and negotiating prices have become increasingly complex and competitive, especially in light of new guidelines under the Affordable Care Act (ACA). Success guarantees that treatments reach patients — and that brands meet or exceed revenue expectations. This report focuses exclusively on US government reimbursement strategy and trends. This study provides actionable insights — drawn from the data and experiences of top-performing life science executives — for winning and maintaining formulary position. Data show US government reimbursement pricing systems and payer relationship management strategies.

Risk-Based Monitoring (PH205)

Simplify risk-based monitoring and use it to facilitate trial processes and anticipate issues related to RBM implementation. The report contains benchmarks comparing in-house and outsourced responsibilities of key clinical roles — trial monitors, data managers, statisticians, and drug safety — for traditional and RBM trials.

Pharmaceutical Lifecycle Management Strategy (PH199)

Increasing focus on LCM throughout a product’s lifecycle will help companies maximize product sales now and better prepare a counter-generics strategy in the future. This study includes data from 100+ pharmaceutical lifecycle management strategies from life science companies of all sizes and across multiple geographic locations.

Medical Information and Call Center Performance (PH206)

Medical information call center staffing benchmarks, including number of agents per manager and outsourcing levels, allow teams to adjust staffing to meet fluctuating project demands.

Clinical Investigator FMV and Compensation Benchmarks (PH202)

Our new clinical investigator FMV study focuses on promoting transparency by building accurate calculation procedures, establishing investigator payment schedules to keep trials on track and organizing successful investigator meetings while staying within a budget.  The report also includes key performance indicators, such as pass-through/direct cost benchmarks, average investigator compensation across nine therapeutic areas, annual compensation limits for principal investigators, and cost-per-attendee metrics for investigator meetings.

Patient-Reported Outcomes (PH203)

Use patient-reported outcomes to guide product development and improve market access initiatives.  Leverage the healthcare consumer perspective to strengthen product value propositions during regulatory approval and reimbursement discussions and to gain insight to drive commercial potential.

Medical Publications Planning (PH201)

Transparency is of growing importance to both the pharmaceutical industry and scientific community.  New methods - open access journals, online portals - have emerged that help companies publish their clinical data. This report is a detailed benchmarking study of current medical publications team structures and strategies.

Managed Markets Account Managers (PH200)

In response to payers’ increased pressure on pharmaceutical and medical device prices, the industry is leveraging new research to bolster the value proposition for new drugs and therapies. However, simply developing this information is not enough.  Managed markets teams are the effective and efficient solution to convey key data to payers.

Health Economics for Medical Devices (PH198)

Medical Device companies are increasingly under pressure to meet payer demands.  To succeed in this environment, device companies arm themselves with health economics data to satisfy payer requirements and maintain optimal price levels.

Pharmaceutical Digital Marketing (PH196)

As regulatory and logistical barriers to digital undertakings lessen, eMarketing is growing more prevalent in pharma.  The digital space unlocks great potential for companies to expand market reach. New online channels, including social media and mobile technology, are finding their way within each company’s marketing media mix.